Stockreport

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

CG Oncology, Inc.  (CGON) 
PDF – Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the [Read more]